| 期刊全称 | Rheumatology and Therapy | ||||||||||||||||||||||||||||||||||||||||||
| 期刊缩写 | RHEUMATOL THER | ||||||||||||||||||||||||||||||||||||||||||
|
涉及主题
（科研通AI识别） |
|||||||||||||||||||||||||||||||||||||||||||
| 期刊介绍 | Aims and Scope Rheumatology and Therapy is an international, open access, peer reviewed, rapid publication journal dedicated to the publication of high-quality clinical (all phases), observational, real-world and health outcomes research around the discovery, development, and use of rheumatologic therapies. Studies relating to diagnosis, pharmacoeconomics, public health, quality of life, and patient care, management, and education are also welcomed. Areas of focus include, but are not limited to, rheumatoid arthritis, gout, gouty arthritis, psoriatic arthritis, osteoarthritis, juvenile idiopathic/rheumatoid arthritis, systemic lupus erythematosus, axial spondyloarthritis, Pompe’s disease, inflammatory joint conditions, musculoskeletal conditions, systemic sclerosis, and fibromyalgia. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, case reports, trial protocols, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Rheumatology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research. Ethics and Disclosures The journal is a member of the Committee on Publication Ethics (COPE) and subscribes to its principles on how to deal with acts of misconduct thereby committing to investigate allegations of misconduct in order to ensure the integrity of research. Content in this journal is peer-reviewed (Single-blind). For more information on our publishing ethics policies, please see here: https://www.springer.com/gp/editorial-policies Rapid Publication The journal’s rapid publication timelines aim for a peer review decision within 2 weeks of submission. If an article is accepted it will be published online 3-4 weeks from acceptance. These rapid timelines are achieved through the combination of a dedicated in-house editorial team, who closely manage article workflow, and an extensive Editorial and Advisory Board who assist with rapid peer review. This allows the journal to support the rapid dissemination of research, whilst still providing robust peer review. Combined with the journal’s open access model this allows for the rapid and efficient communication of the latest research and reviews, allowing the advancement of rheumatologic therapies. Personal Service The journal’s dedicated in-house editorial team offer a personal “concierge service” meaning that authors will always have a personal point of contact able to update them on the status of their manuscript. The editorial team check all manuscripts to ensure that articles conform to the most recent COPE, GPP and ICMJE publishing guidelines. This supports the publication of ethically sound and transparent research. We also encourage pre-submission enquiries and are always happy to provide a confidential assessment of manuscripts. Digital Features Rheumatology and Therapy offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by key summary points, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article. The journal also provides the option to include various types of digital features including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations. All additional features are peer reviewed to the same high standard as the article itself. If you consider that your paper would benefit from the inclusion of a digital feature, please let us know. Our editorial team are able to create high-quality slide decks and infographics in-house, and video abstracts through our partner Research Square, and would be happy to assist in any way we can. For further information about digital features, please contact the journal editor (see ‘Contact the Journal’ for email address), and see the ‘Guidelines for digital features and plain language summaries’ document under ‘Submission guidelines’. For examples of digital features please visit: https://springerhealthcare.com/expertise/publishing-digital-features/ Preprints We encourage posting of preprints of primary research manuscripts on preprint servers, authors' or institutional websites, and open communications between researchers whether on community preprint servers or preprint commenting platforms. Posting of preprints is not considered prior publication and will not jeopardize consideration in our journals. Authors should disclose details of preprint posting during the submission process or at any other point during consideration in the journal. Once the manuscript is published, it is the author's responsibility to ensure that the preprint record is updated with a publication reference, including the DOI and a URL link to the published version of the article on the journal website. Please see here for further information on preprint sharing: https://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/submission/1302#c16721550 Peer Review Process Upon submission, manuscripts are assessed by the editorial team to ensure they fit within the aims and scope of the journal and are also checked for plagiarism. All suitable submissions are then subject to a comprehensive single-blind peer review. Reviewers are selected based on their relevant expertise and publication history in the subject area. The journal has an extensive pool of editorial and advisory board members who have been selected to assist with peer review based on the afore-mentioned criteria. At least two extensive reviews are required to make the editorial decision. Where reviewer recommendations are conflicted, the editorial board will be contacted for further advice and a presiding decision. Manuscripts are then either accepted, rejected or authors are required to make major or minor revisions (both reviewer comments and editorial comments may need to be addressed). Once a revised manuscript is re-submitted, it is assessed along with the responses to reviewer comments and if it has been adequately revised it will be accepted for publication. Accepted manuscripts are then copyedited and typeset by the production team before online publication. Appeals against decisions following peer review are considered on a case-by-case basis and should be sent to the journal editor, and authors are welcome to make rebuttals against individual reviewer comments if appropriate. Considering the time and effort required for a detailed peer review we reward our regular reviewers with the opportunity to publish without publication fees (pending peer review) for every three reviews completed per calendar year. Copyright Rheumatology and Therapy is published under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, click here: http://creativecommons.org/licenses/by-nc/4.0. Publication Fees Upon acceptance of an article, authors will be required to pay the mandatory Rapid Service Fee of €5,250/$6,000/£4,300. The journal will consider fee discounts and waivers for developing countries and this is decided on a case-by-case basis. Open Access All articles published by Rheumatology and Therapy are published open access. Contact For more information about the journal, including pre-submission enquiries, please contact charlotte.maddocks@springernature.com. | ||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||
| 期刊ISSN | print: 2198-6576on-line: 2198-6584 | ||||||||||||||||||||||||||||||||||||||||||
| 2023最新影响因子 (2024年6月20日公布) 与上一年的差值 |
2.9↓ 0.9 | ||||||||||||||||||||||||||||||||||||||||||
| 历年影响因子 |
|
||||||||||||||||||||||||||||||||||||||||||
| 历年发表/被引量 （科研通AI通过大数据分析） 最后更新日期：2025-04-27 |
|
||||||||||||||||||||||||||||||||||||||||||
| h-index（2021） | 暂无h-index数据 | ||||||||||||||||||||||||||||||||||||||||||
| 自引率 | 6.90% | ||||||||||||||||||||||||||||||||||||||||||
| 涉及的研究领域 | RHEUMATOLOGY- | ||||||||||||||||||||||||||||||||||||||||||
| 中科院2025年分区 （2025年3月20日发布） |
|
||||||||||||||||||||||||||||||||||||||||||
| WOS期刊分区 （2024年6月20日公布） |
JCR学科分类
JCI学科分类
|
||||||||||||||||||||||||||||||||||||||||||
| 中科院SCI期刊分区 （2023年12月升级版） |
|
||||||||||||||||||||||||||||||||||||||||||
| 中科院SCI期刊分区 （2022年12月升级版） |
|
||||||||||||||||||||||||||||||||||||||||||
| 中科院SCI期刊分区 （2021年12月基础版） |
|
||||||||||||||||||||||||||||||||||||||||||
| 中科院SCI期刊分区 （2021年12月升级版） |
|
||||||||||||||||||||||||||||||||||||||||||
| 中科院《国际期刊预警名单（试行）》名单 |
2024年02月发布的2024版：不在预警名单中 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2021年01月发布的2020版：不在预警名单中 |
||||||||||||||||||||||||||||||||||||||||||
| 期刊主页 |
（系统检测到多个链接，仅供参考，如有错误，请通过页面底部反馈） |
||||||||||||||||||||||||||||||||||||||||||
| 投稿网址 | https://www.editorialmanager.com/rhth/ | ||||||||||||||||||||||||||||||||||||||||||
| 编辑部地址 | ONE NEW YORK PLAZA, SUITE 4600 , NEW YORK, United States, NY, 10004 | ||||||||||||||||||||||||||||||||||||||||||
| 出版商 | Springer Healthcare | ||||||||||||||||||||||||||||||||||||||||||
| 出版国家（地区） | ENGLAND | ||||||||||||||||||||||||||||||||||||||||||
| 出版语言 | English | ||||||||||||||||||||||||||||||||||||||||||
| 出版周期 | 6 issues per year | ||||||||||||||||||||||||||||||||||||||||||
| 创刊年份 | 2014 | ||||||||||||||||||||||||||||||||||||||||||
| 每年出版文章数 | 136 | ||||||||||||||||||||||||||||||||||||||||||
| Gold OA文章占比 | 99.38% | ||||||||||||||||||||||||||||||||||||||||||
| 原创研究文献占比 （排除综述） |
88.04% | ||||||||||||||||||||||||||||||||||||||||||
| SCI收录类型 |
Science Citation Index Expanded (SCIE) Directory of Open Access Journals (DOAJ) |
||||||||||||||||||||||||||||||||||||||||||
| PubMed链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=2198-6576%5BISSN%5D | ||||||||||||||||||||||||||||||||||||||||||
| 平均审稿周期 | 网友分享经验： 6 Weeks |
||||||||||||||||||||||||||||||||||||||||||
| 平均录用比例 | 网友分享经验： |
||||||||||||||||||||||||||||||||||||||||||
| 相关链接 |
LetPub
您可以在上述网站查看该期刊的网友互动，及期刊影响力的其它指标。
|
||||||||||||||||||||||||||||||||||||||||||
皖公网安备34019202002308
